UroGen shareholders elect directors and approve compensation policy and equity plan amendment at 2024 annual meeting

UroGen Pharma Ltd.

All eight director nominees elected with over 24M votes for each; broker non-votes 6.75M.
2024 Compensation Policy approved: 22.4M for, 3.4M against, 513K abstentions, 6.75M broker non-votes.
Amendment to 2017 Equity Plan adding 800K shares approved: 22.7M for, 3.1M against, 548K abstentions.
Advisory vote on named executive officer compensation passed: 22.6M for, 3.1M against, 553K abstentions.
PricewaterhouseCoopers LLP ratified as auditor: 33.0M for, 8,345 against, 7,053 abstentions; no broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.